Vertex Pharmaceuticals' Q4 2024 earnings report

CASGEVY™ CRISPR-Based Therapy for Beta Thalassemia Approved in England

Aug 7, 2024, 11:25 PM

Patients in England suffering from a rare blood disorder known as transfusion-dependent beta thalassemia will soon have access to the world's first CRISPR-based medicine, CASGEVY™. This development follows a reimbursement agreement reached between Vertex Pharmaceuticals and U.K. officials. The National Health Service (NHS) will begin rolling out the gene therapy, which is a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, marking a significant advancement in the treatment of this condition.